Tripeptide · Fact sheet
KPV
Also known as Lys-Pro-Val
KPV is a three-amino-acid peptide investigated for inflammatory signaling, especially in the gut. Cell and mouse results are promising research leads, but human treatment benefits and safety have not been established.
What is KPV?
KPV corresponds to the final three amino acids of alpha-melanocyte-stimulating hormone. Researchers have studied how a peptide transporter brings it into cells.
Benefits people look for
Readers look for relief from gut inflammation, skin irritation, and broad inflammatory symptoms. These claims extend beyond the human evidence available in the cited research.
What the evidence supports
- KPV reduced inflammatory signaling and disease measures in experimental colitis models.
- A mouse cancer model offers a mechanistic lead, not evidence that KPV prevents or treats human cancer.
All research areas
- Inflammatory signaling
- Experimental colitis
- Colitis-associated cancer models
Anecdotal reports & lived experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens.
No attributable personal reports are summarized here yet. The benefits above describe research interests; the side effects below come from the cited medical sources.
We do not fill this gap with unsourced testimonials or estimated success rates.
Side effects & risks
- FDA reports no identified human exposure data and insufficient safety information.
- A useful human side-effect frequency cannot be calculated from cell or mouse experiments.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research: how strong is it?
Mostly animal or lab researchThe central findings come from cell systems and mouse models of colitis and inflammation-associated cancer. Human biopsy observations in a paper are not a trial of KPV treatment.
Selected research to read
Cell experiments and two mouse colitis models.
Animal treatment results; human tissue observations do not establish treatment efficacy.
FDA approval & research status
KPV has no FDA-approved therapeutic use. The cited work is preclinical, and FDA describes a lack of human exposure data in its compounding assessment.
No FDA-approved use is documented in the records summarized on this page.
Preclinical evidence; no FDA approval
KPV has no FDA-approved therapeutic use. The cited work is preclinical, and FDA describes a lack of human exposure data in its compounding assessment.
This summarizes the cited product or research record. Trial phases do not establish successful completion of earlier stages, and a stopped program is not ongoing development. Approval applies only to the labeled product, use and population.
What we still don’t know
- Human benefits for specific gut or skin conditions
- Long-term and uncommon adverse effects
- Interactions and reliable product exposure
The takeaway
KPV belongs in the preclinical research category; an anti-inflammatory mechanism is not an established treatment benefit.
Sources & further reading
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- 1fdaFDA: safety concerns for selected bulk substances
Ingredient-specific safety findings; compounding review is not drug approval.
- 2pubmedPepT1-mediated KPV uptake and intestinal inflammation
Cell experiments and two mouse colitis models.
- 3pubmedKPV in a murine colitis-associated cancer model
Animal treatment results; human tissue observations do not establish treatment efficacy.